trending Market Intelligence /marketintelligence/en/news-insights/trending/hR9ZwsDC-aJSnjDh1U-bdg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US FDA approves Eli Lilly, Boehringer Ingelheim's type 2 diabetes drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA approves Eli Lilly, Boehringer Ingelheim's type 2 diabetes drug

The U.S. FDA approved Eli Lilly & Co. and Boehringer Ingelheim's Synjardy XR for adults with type 2 diabetes.

Synjardy XR is a combination of two drugs formulated to be taken once a day. The approval was based on clinical trials examining the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea in the treatment of adults with type 2 diabetes.

The drug is co-marketed by Eli Lilly and Boehringer Ingelheim. Synjardy XR is the eighth FDA-approved treatment from Eli Lilly and Boehringer's partnership.